Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
4.810
+0.020 (0.42%)
Sep 25, 2026, 11:11 AM EDT - Market open
Oramed Pharmaceuticals Revenue
In the year 2025, Oramed Pharmaceuticals had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
200.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
| Dec 31, 2022 | 2.70M | 1.80M | 199.00% |
| Dec 31, 2021 | 904.00K | -1.80M | -66.56% |
| Aug 31, 2021 | 2.70M | -7.00K | -0.26% |
| Aug 31, 2020 | 2.71M | 7.00K | 0.26% |
| Aug 31, 2019 | 2.70M | 254.00K | 10.37% |
| Aug 31, 2018 | 2.45M | -7.00K | -0.29% |
| Aug 31, 2017 | 2.46M | 1.82M | 283.15% |
| Aug 31, 2016 | 641.00K | - | - |
| Aug 31, 2015 | - | - | - |
| Aug 31, 2014 | - | - | - |
| Aug 31, 2013 | - | - | - |
| Aug 31, 2012 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
| Aug 31, 2007 | - | - | - |
| Aug 31, 2006 | - | - | - |
| Aug 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Alpha Cognition | 15.26M |
| Surrozen | 11.51M |
| Adagene | 9.29M |
| Sol-Gel Technologies | 1.80M |
| Veraxa Biotech AG | 29.54K |
ORMP News
- 6 weeks ago - Oramed Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Oramed Pharmaceuticals Proxy statement: Proxy filing - Filings
- 7 weeks ago - Oramed Pharmaceuticals Proxy statement: Proxy filing - Filings
- 3 months ago - Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - PRNewsWire
- 3 months ago - Oramed to join Russell 2000 and 3000 indexes - TheFly
- 3 months ago - Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PRNewsWire
- 4 months ago - Oramed Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 6 months ago - Oramed Pharmaceuticals Annual report: Q4 2025 - Filings